US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News
Executive Summary
This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included the revelation by federal prosecutors they may bring additional charges against former drug company CEO Martin Shkreli, which would be on top of the seven criminal counts he already is facing, including securities fraud; and a recommendation by an FDA panel that the risk plans for opioids need to be revised to cover immediate-release versions of those products, rather than just the extended-release and long-acting drugs, and require mandatory, instead of voluntary, prescriber training; plus other Washington news.